Cargando…

Investigating the feasibility of using Ethos generated treatment plans for head and neck cancer patients

The Varian Ethos treatment platform is designed to automatically create complex RT treatment plans, reducing both workload and operator variability in plan quality. The aim of this study is to evaluate the quality of Ethos-generated head and neck (H&N) treatment plans. Ethos plans were created f...

Descripción completa

Detalles Bibliográficos
Autores principales: El-qmache, Adam, McLellan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511846/
https://www.ncbi.nlm.nih.gov/pubmed/37744525
http://dx.doi.org/10.1016/j.tipsro.2023.100216
Descripción
Sumario:The Varian Ethos treatment platform is designed to automatically create complex RT treatment plans, reducing both workload and operator variability in plan quality. The aim of this study is to evaluate the quality of Ethos-generated head and neck (H&N) treatment plans. Ethos plans were created for ten previous H&N patients and these were compared with the original clinical plans generated in Eclipse. Ethos automatically creates several plans with different field arrangements for each patient. All plans were compared quantitatively using: dose-volume metrics; dose conformity; dose heterogeneity and monitor units (MU). In addition, two H&N Oncologists assessed the clinical acceptability of the Ethos plans. Consultant 1 judged there to be at least three clinically acceptable Ethos plans for 9 out of 10 patients reviewed. Consultant 2 approved of at least two Ethos plans for 5 out of 5 patients reviewed. The Ethos plans’ average dose metrics were comparable to the clinical plans. The average plan MU was similar for Eclipse and Ethos VMAT plans. The average plan MU for Ethos IMRT plans was larger with respect to all VMAT plans. The Ethos Treatment Planning system is capable of automatically creating good quality treatment plans for a range of H&N cancer patients.